CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)), fully human, monoclonal antibody being developed as a treatment for COVID-19 associated ARDS and Pediatric Crohn’s Disease. CERC-002 is currently initiating a proof-of-concept trial for the prevention or COVID-19 ARDS.
CERC-002 is currently in a Phase I study in adult Crohn’s patients and has recently dosed the first patient. We anticipate initial data in the first half of 2020.
CERC-006 is an mTORC1/2 inhibitor (a class of drugs that inhibit the mammalian target of rapamycin) targeted towards Complex Lymphatic Malformations (LM). LM patients often have activating mutations along the PI3K/AKT/mTOR pathway and sirolimus is an mTORC1 inhibitor that has demonstrated clinical utility in LM. CERC-006 has the potential to improve on both the safety and efficacy of mTOR inhibition in LM. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-006 in LM patients in 2020.
CERC-007 is a fully human anti-IL-18 monoclonal antibody with the potential to address multiple auto-inflammatory diseases, including Adult Onset Still's Disease (AOSD) and Multiple Myeloma (MM). IL-18 is a pro-inflammatory cytokine; patients with ASOD and MM show elevated levels of IL-18. Cerecor seeks to initiate a Phase 1b/2a proof-of-concept study of CERC-007 in ASOD and MM patients in 2020.
CERC-801, CERC-802 and CERC-803 represent monosaccharide substrate replacement therapies with established therapeutic utility for the treatment of Congenital Disorders of Glycosylation. Oral administration of these substrates replenishes critical metabolic intermediates that are reduced or absent due to genetic mutation, overcoming single enzyme defects to support glycoprotein synthesis, maintenance and function.
Cerecor is a Maryland-based biopharmaceutical company focused on the development and commercialization of products in Rare Pediatric and Orphan diseases.
Our pipeline is one of the most promising in the biotech industry. We have six clinical-stage, rare disease assets characterized as novel, first-in-class medicines with the opportunity for multiple product launches through 2023.